Status: Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.

Participants needed: 150

Trial details

Age: 18+Biological sex: AllType: ObservationalSponsor: Antalya Training and Research HospitalUpdated: Apr 30, 2026Locations: 25

Eligibility criteria

Signed informed consent form. [+4]

Patients who are not receiving atezolizumab for the treatment of lung cancer acc... [+2]

Status: Recruiting

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma.

Participants needed: 27

Trial details

Age: 18-75Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Dec 3, 2024Locations: 1

Eligibility criteria

Clinical diagnosis of HCC. [+9]

Diffuse HCC; [+10]